Review of NICE Technology Appraisal Guidance No. 70; Guidance on the use of imatinib for chronic myeloid leukaemia, and No. 251; Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia

The Institute was proposing that both pieces of guidance should be transferred to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, both TA70 and TA251 will move to the static technology appraisals list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

October 2014

Attachments

Appendix A – Decision paper presented to the Institute’s Guidance Executive